Prophylactic acetylcysteine usage for prevention of contrast nephropathy after coronary angiography

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 4, 2005, Pages 464-467

  Gulel, Okan ^a,d   Keles, Telat ^b   Eraslan, Hakan ^c   Aydogdu, Sinan ^c   Diker, Erdem ^c   Ulusoy, Vasfi ^c  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^b ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d Universite Lojmanlari   (Turkey)

Author keywords

Acetylcysteine; Contrast nephropathy; Coronary angiography

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; CONTRAST MEDIUM; OXYGEN RADICAL; PLACEBO; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTRAST RADIOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG USE; FEMALE; HIGH RISK PATIENT; HUMAN; HYDRATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; OSMOLALITY; PRIORITY JOURNAL; PROPHYLAXIS;

ACETYLCYSTEINE; AGED; ANTIOXIDANTS; BLOOD UREA NITROGEN; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CREATININE; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 26044442775     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000176730.59443.dd     Document Type: Article

References (15)

1. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med. 1997;103:368-375.
2. Bakris GL, Lass N, Gaber AO, et al. Radiocontrast medium induced declines in renal function: a role for oxygen free radicals. Am J Physiol. 1990;258:F115-F120.
3. Baliga R, Ueda N, Walker PD, et al. Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis. 1997;29:465-477.
4. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180-184.
5. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent associated nephrotoxicity. J Am Coll Cardiol. 2002;40:298-303.
6. Briguori C, Colombo A, Violante A, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J. 2004;25:206-211.
7. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162:329-336.
8. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62:2202-2207.
9. Boccalandro F, Amhad M, Smalling RW, et al. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographie contrast. Catheter Cardiovasc Interv. 2003;58:336-341.
10. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radio-contrast induced nephropathy. Catheter Cardiovasc Interv. 2002;57:279-283.
11. Baker CS, Wragg A, Kumar S, et al. A rapid protocol for the prevention of contrast induced renal dysfunction: The RAPPID study. J Am Coll Cardiol. 2003;41:2114-2118.
12. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40:1383-1388.
13. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention. JAMA. 2003;289:553-558.
14. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW Acetylcysteine to prevent angiography related renal tissue injury (The APART trial). Am J Cardiol. 2002;89:356-358.
15. Duong MH, MacKenzie TA, Malenka DJ. N-Acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Catheter Cardiovasc Interv. 2005;64:471-479.